Trial Profile
A Phase III, Double-Blind, Randomized Study of IDEC-C2B8 in Patients with Childhood-onset Refractory Nephrotic Syndrome.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Nephrotic syndrome
- Focus Adverse reactions; Therapeutic Use